Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rhabdomyosarcoma, Alveolar × Dactinomycin × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Rhabdomyosarcoma, Embryonal 2 Rhabdomyosarcoma 2 Stage I Mixed Cell Type Kidney Wilms Tumor 1 Sarcoma, Ewing 1 Rhabdomyosarcoma, Alveolar 1 Pleuropulmonary blastoma 1

Interventions

temsirolimus 1 Vinorelbine 1 Vincristine 1 Sirolimus 1 Radiotherapy 1 Radiation 1 Irinotecan 1 Dactinomycin 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02567435 2026-03-17

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting

325 enrolled 14 charts

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡